ARS Pharmaceuticals reports 2025 key strategic priorities

2025 Key Strategic Priorities for Accelerating neffy U.S. Sales and Recent Highlights: Increase demand and traction among target prescribers, with continued sales force and medical science liaison engagement, expansion of the company’s neffy Experience Program, and rollout of additional continuing medical education programs; More than 3,000 healthcare providers have prescribed neffy to date, of which 80 percent are in the highest decile categories for prescribing epinephrine; More than 1,750 healthcare providers have participated in the neffy Experience Program. Expand commercial access of neffy; Express Scripts, the second largest pharmacy benefits manager in the U.S., added neffy to its commercial national formularies in November 2024; On track for more than 60 percent commercial coverage by the end of the first quarter of 2025, and more than 80 percent commercial coverage by the end of the third quarter of 2025; Contracting consistent with target long-term total gross-to-net revenue of 50 percent. Increase consumer awareness of neffy and availability of a needle-free option; Preparations are underway to launch a branded neffy direct-to-consumer marketing campaign beginning in May 2025; Designed to build momentum ahead of the ‘back-to-school’ season, the campaign will extend throughout the summer, driving brand recognition and encouraging patients to request neffy by name; In parallel, to amplify public awareness of the needle-free epinephrine option, Food Allergy Research and Education is set to launch a public service announcement campaign featuring a celebrity ambassador with ARS Pharma support later this year. Obtain approval of neffy 1 mg for children who weigh 15 to 30 kg; The sNDA filed with the U.S. FDA for neffy for children who weigh 15 to 30 kg has a Prescription Drug User Fee Act target action date of March 6, 2025. Based on review timelines and subject to approval, product availability of neffy 1 mg is expected in the second quarter of 2025